Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic Testing for PPI Dosing in Children
NCT02794844Phase 4Completed
- Sponsor
- Nemours Children's Health
- Start
- Jul 2016
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in gastroesophageal reflux disease (GERD), sponsored by Nemours Children's Health. Primary endpoints: Count of Patients Agreeing to Volunteer for the Study at 12 months, Count of Patients Reporting Efficacy and Toxicity Data at 12 months and 3 more. Started Jul 2016; status: completed.
02
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02794844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794844.